Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Inflammation AND sPLA2 AND atherosclerosis AND phospholipase:

Search results

Items: 1 to 20 of 39

1.

Tracking of secretory phospholipase A2 enzyme activity levels from childhood to adulthood: a 21-year cohort.

Chung O, Juonala M, Mallat Z, Hutri-Kähönen N, Viikari JSA, Raitakari OT, Magnussen CG.

J Pediatr (Rio J). 2018 Feb 21. pii: S0021-7557(17)31168-3. doi: 10.1016/j.jped.2018.01.002. [Epub ahead of print]

2.

PX-18 Protects Human Saphenous Vein Endothelial Cells under Arterial Blood Pressure.

Kupreishvili K, Stooker W, Emmens RW, Vonk ABA, Sipkens JA, van Dijk A, Eijsman L, Quax PH, van Hinsbergh VWM, Krijnen PAJ, Niessen HWM.

Ann Vasc Surg. 2017 Jul;42:293-298. doi: 10.1016/j.avsg.2016.10.063. Epub 2017 Mar 11.

PMID:
28300679
3.

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells.

Xie Q, Zhang D.

Int Heart J. 2017 Feb 7;58(1):115-124. doi: 10.1536/ihj.16-163. Epub 2017 Jan 24.

4.

Inhibition of Human Group IIA-Secreted Phospholipase A2 and THP-1 Monocyte Recruitment by Maslinic Acid.

Yap WH, Ahmed N, Lim YM.

Lipids. 2016 Oct;51(10):1153-1159. doi: 10.1007/s11745-016-4186-1. Epub 2016 Aug 19.

PMID:
27540737
5.

[Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].

Chen J, Cai HW, Miao J, Xu XM, Mao W.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jun;36(6):703-8. Chinese.

PMID:
27491230
6.

Metabolic regulation by secreted phospholipase A2.

Sato H, Taketomi Y, Murakami M.

Inflamm Regen. 2016 May 21;36:7. doi: 10.1186/s41232-016-0012-7. eCollection 2016. Review.

7.

Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.

Yarla NS, Bishayee A, Vadlakonda L, Chintala R, Duddukuri GR, Reddanna P, Dowluru KS.

Curr Drug Targets. 2016;17(16):1940-1962. Review.

PMID:
26212262
8.

HDL in infectious diseases and sepsis.

Pirillo A, Catapano AL, Norata GD.

Handb Exp Pharmacol. 2015;224:483-508. doi: 10.1007/978-3-319-09665-0_15. Review.

9.

Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.

Curcic S, Holzer M, Frei R, Pasterk L, Schicho R, Heinemann A, Marsche G.

Biochim Biophys Acta. 2015 Feb;1851(2):184-93. doi: 10.1016/j.bbalip.2014.11.010. Epub 2014 Nov 24.

10.

Roles of secreted phospholipases A₂ in the mammalian immune system.

Krizaj I.

Protein Pept Lett. 2014;21(12):1201-8. Review.

PMID:
25141938
11.

Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease.

Quach ND, Arnold RD, Cummings BS.

Biochem Pharmacol. 2014 Aug 15;90(4):338-48. doi: 10.1016/j.bcp.2014.05.022. Epub 2014 Jun 4. Review.

12.

Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Cavigiolio G, Jayaraman S.

J Biol Chem. 2014 Apr 4;289(14):10011-23. doi: 10.1074/jbc.M113.525717. Epub 2014 Feb 12.

13.

Thyroid hormone status regulates the expression of secretory phospholipases.

Sharma P, Levesque T, Boilard E, Park EA.

Biochem Biophys Res Commun. 2014 Jan 31;444(1):56-62. doi: 10.1016/j.bbrc.2014.01.003. Epub 2014 Jan 16.

14.

Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial.

Lavi S, Thorpe K, Luca MC, Liuni A, Floras J, Horlick EM, Ing D, Osten MD, Overgaard CB, Lan J, Parker JD, Cantor WJ, Džavík V.

Can J Cardiol. 2012 Mar-Apr;28(2):215-21. doi: 10.1016/j.cjca.2011.11.007. Epub 2012 Jan 26.

PMID:
22281412
15.

Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx.

Kupreishvili K, Baidoshvili A, ter Weeme M, Huybregts MA, Krijnen PA, Van Hinsbergh VW, Stooker W, Eijsman L, Niessen HW.

J Heart Valve Dis. 2011 Jan;20(1):29-36.

PMID:
21404895
16.

sPLA2: linking atherosclerosis to aneurysm progression.

Federici M, Menghini R.

Atherosclerosis. 2011 Jan;214(1):41-2. doi: 10.1016/j.atherosclerosis.2010.10.031. Epub 2010 Nov 10. No abstract available.

PMID:
21122857
17.

Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling.

Gora S, Maouche S, Atout R, Wanherdrick K, Lambeau G, Cambien F, Ninio E, Karabina SA.

FASEB J. 2010 Sep;24(9):3284-97. doi: 10.1096/fj.09-146852. Epub 2010 Apr 29.

PMID:
20430794
18.

Extracellular phospholipases in atherosclerosis.

Karabina SA, Gora S, Atout R, Ninio E.

Biochimie. 2010 Jun;92(6):594-600. doi: 10.1016/j.biochi.2010.02.002. Epub 2010 Feb 12. Review.

PMID:
20153800
19.

Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis.

Oörni K, Kovanen PT.

Curr Opin Lipidol. 2009 Oct;20(5):421-7. doi: 10.1097/MOL.0b013e32832fa14d. Review.

PMID:
19593123
20.

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Järvinen H, Keech AC, Taskinen MR.

J Am Coll Cardiol. 2008 Dec 16;52(25):2190-7. doi: 10.1016/j.jacc.2008.09.049.

Supplemental Content

Loading ...
Support Center